Authors: Dantzig, AH Law, KL Cao, J Starling, JJ

Citation: Ah. Dantzig et al., Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic, CURR MED CH, 8(1), 2001, pp. 39-50

Authors: Suh, N Glasebrook, AL Palkowitz, AD Bryant, HU Burris, LL Starling, JJ Pearce, HL Williams, C Peer, C Wang, YP Sporn, MB

Citation: N. Suh et al., Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer, CANCER RES, 61(23), 2001, pp. 8412-8415

Authors: Norman, BH Dantzig, AH Kroin, JS Law, KL Tabas, LB Shepard, RL Palkowitz, AD Hauser, KL Winter, MA Sluka, JP Starling, JJ

Citation: Bh. Norman et al., Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146., BIOORG MED, 9(23), 1999, pp. 3381-3386

Authors: Dantzig, AH Shepard, RL Law, KL Tabas, L Pratt, S Gillespie, JS Binkley, SN Kuhfeld, MT Starling, JJ Wrighton, SA

Citation: Ah. Dantzig et al., Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities, J PHARM EXP, 290(2), 1999, pp. 854-862